[Perioperative management of focal liver diseases by ofloxacin].
Perioperative use of ofloxacin for prophylaxis was investigated in 20 patients with focal hepatic formations (hemangioma, adenocarcinoma, echinococcosis). First dose of ofloxacin (200 mg) was given intravenously 15 min before operation. After operation ofloxacin was used intravenously (400 mg daily) for 5 days. Pharmacokinetic investigation demonstrated that perioperative intravenous use of ofloxacin provided concentrations in blood and hepatic tissue satisfactory for potential microflore inhibition. Immunological monitoring demonstrated positive dynamics on 5-7 days after operation. dynamics depended on nosology of the focal hepatic formation. Ofloxacin use for prophylaxis in the operated patients with focal hepatic formations was efficient for profilaxy of postoperation infective complications.
Khlebnikov
E P
EP
A.V. Vishnevsky Institute of Surgery, Russian Academy of Medical Sciences, Moscow.
Elagina
L V
LV
Vishnevskiĭ
V A
VA
Kybyshkin
V A
VA
Izotova
G N
GN
Pavlova
M V
MV
Ikramov
R Z
RZ
D000230:Adenocarcinoma / Q000276:immunology / Q000601:surgery*; D000328:Adult; D000368:Aged; D000890:Anti-Infective Agents / Q000627:therapeutic use*; D019072:Antibiotic Prophylaxis; D000917:Antibody Formation / Q000187:drug effects; D004444:Echinococcosis, Hepatic / Q000276:immunology / Q000601:surgery*; D005260:Female; D006391:Hemangioma / Q000276:immunology / Q000601:surgery*; D006801:Humans; D007111:Immunity, Cellular / Q000187:drug effects; D008113:Liver Neoplasms / Q000276:immunology / Q000601:surgery*; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use*; D019990:Perioperative Care; D011183:Postoperative Complications / Q000382:microbiology / Q000517:prevention & control*; D013530:Surgical Wound Infection / Q000517:prevention & control
D000890:Anti-Infective Agents; D015242:Ofloxacin